A multicentre randomised double-blind (sponsor-unblinded) placebo-controlled study with open label extension to investigate the safety and tolerability pharmacokinetics pharmacodynamics and efficacy of GSK2982772 in subjects with active ulcerative colitis
Brief description of study
The primary objective will be to investigate the safety and tolerability of repeat oral doses of GSK2982772 60 mg or placebo three times daily for 42 days (park A) followed by open label with GSK2982772 60 mg three times daily for 42 days (Part B). In addition to pharmacokinetics (PK), a number of experimental and clinical endpoints will be employed to obtain information on the pharmacodynamics (PD), and preliminary efficacy in subjects with active UC.
Clinical Study Identifier: s16-00180
ClinicalTrials.gov Identifier: NCTs16-00180
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
